Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

I agree and think it is a generally confusing chain of events.

*Issuing stock to close out the prior deal at the same time they are trying to repurchase and retire shares is weird.

*Plus, they really have no obvious need - and have said so numerous times - to raise additional cash.

*They will have about $300 million additional dollars in the kitty (broadly speaking) after closing out the prior debenture, at close to zero cost, but there is the dilution effect of the 9 million newly issued shares.

Head scratching. I'm assuming a net benefit when all the dust settles, but it is hazy.